A recent study led by Bruce Boman of Christiana Care Health System, found that colon cancer stem cell activity may be inhibited by retinoic acid signaling. Retinoic acid, a vitamin A–derived molecule often found in topical anti-aging products (Retin-A), is used in cancer treatment due to its affect on cell development.
Colorectal cancer is the second leading cause of cancer-related deaths in the United States. It can be difficult to treat due to drug resistance; this discovery may help oncologists target these cancers with more success.
“Our findings point to a number of possibilities for developing more effective stem cell targeting therapies for advanced colorectal cancer,” Dr. Boman said.
The paper, published in the Oct. 5 issue of Oncotarget, is co-authored by former University of Delaware student researcher Shirin Modarai (who currently works for Christiana Care), among others.
Read the findings
Join our growing Slack community
Join 5,000 tech professionals and entrepreneurs in our community Slack today!
Donate to the Journalism Fund
Your support powers our independent journalism. Unlike most business-media outlets, we don’t have a paywall. Instead, we count on your personal and organizational contributions.
